MicroRNAs as Potential Tools for Predicting Cancer Patients' Susceptibility to SARS-CoV-2 Infection and Vaccination Response

Cells. 2022 Jul 23;11(15):2279. doi: 10.3390/cells11152279.

Abstract

Coronavirus disease (COVID-19) is an infectious disease that is caused by a highly contagious and severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). This infection started to spread across the world in 2019 and rapidly turned into a global pandemic, causing an urgent necessity for treatment strategies development. The mRNA vaccines against SARS-CoV-2 can trigger an immune response, providing genetic information that allows the production of spike glycoproteins. MiRNAs play a crucial role in diverse key cellular processes, including antiviral defense. Several miRNAs are described as key factors in SARS-CoV-2 human infection through the regulation of ACE2 levels and by the inhibition of SARS-CoV-2 replication and spike expression. Consequently, these molecules have been considered as highly promising biomarkers. In numerous human malignancies, it has been recognized that miRNAs expression is dysregulated. Since miRNAs can target SARS-CoV-2-associated mRNAs, in cancer patients, the deregulation of these molecules can impair the immune response to the vaccines. Therefore, in this review, we propose a miRNA profile of seven SARS-CoV-2-related miRNAs, namely miR-214, miR-98-5p, miR-7-5p, miR-24-3p, miR-145-5p, miR-223-3p and miR-15b-5p, that are deregulated in a high number of cancers and have the potential to be used as prognostic biomarkers to stratify cancer patients.

Keywords: COVID-19; cancer; immune response; miRNAs; vaccine.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Neoplasms* / genetics
  • RNA, Messenger / genetics
  • SARS-CoV-2
  • Vaccination

Substances

  • COVID-19 Vaccines
  • MIRN145 microRNA, human
  • MIRN214 microRNA, human
  • MIRN98 microRNA, human
  • MicroRNAs
  • RNA, Messenger

Grants and funding

This research was funded by the Portuguese national funding agency for science, research and technology (FCT—Fundação para a Ciência e a Tecnologia), project reference: UIDP/00776/2020). TD is a research fellow from LPCC-NRN (LPCC-NRN-2022-TD) and FD has a junior researcher contract funded by UIDP/00776/2020-4B.